• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Sholehvar David

    11/14/23 7:55:41 PM ET
    $NVTA
    Medical Specialities
    Health Care
    Get the next $NVTA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Sholehvar David

    (Last) (First) (Middle)
    C/O INVITAE CORPORATION
    1400 16TH STREET

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/13/2023
    3. Issuer Name and Ticker or Trading Symbol
    Invitae Corp [ NVTA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Operating Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit List: Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ David Sholehvar 11/14/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NVTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVTA

    DatePrice TargetRatingAnalyst
    7/5/2023Underweight
    JP Morgan
    5/15/2023Mkt Perform → Underperform
    Raymond James
    1/31/2023$2.00Neutral → Sell
    Goldman
    8/25/2022$1.00Underperform
    Credit Suisse
    8/10/2022Neutral → Underweight
    JP Morgan
    7/26/2022$8.00 → $2.50Outperform → Market Perform
    Cowen
    7/21/2022Outperform → Mkt Perform
    Raymond James
    7/20/2022Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $NVTA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Invitae Corporation

      25-NSE - Invitae Corp (0001501134) (Subject)

      2/21/24 8:59:54 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Invitae Corp (0001501134) (Filer)

      2/14/24 6:59:56 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Invitae Corp (0001501134) (Filer)

      2/6/24 5:07:32 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Announces Winning Bid for Select Assets of Invitae

      Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.

      4/24/24 9:27:00 PM ET
      $LH
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Enters into Agreement with Labcorp for Sale of Business

      – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis

      4/24/24 9:19:00 PM ET
      $LH
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Publishes its Environmental, Social and Governance (ESG) Report

      – Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring c

      4/22/24 12:43:00 PM ET
      $NVTA
      Medical Specialities
      Health Care